• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McDonagh M. Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Feb.

Cover of Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod

Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet].

Show details

Appendix BExcluded studies

The following full-text publications were considered for inclusion but failed to meet the criteria for this report.

Excluded studiesExclusion code
Placebo-controlled trials
Radue EW, O’Connor P, Polman C, et al. Oral fingolimod (FTY720) reduces inflammatory activity vs placebo in relapsing remitting multiple sclerosis: 24 month MRI results from a randomized, double-blind, multicenter phase III study (FREEDOMS) [presentation]. Presented at: The America Academy of Neurology 62nd Annual Meeting. Vol Toronto, Canada: April 10–17, 2010; 2010.2
Kappos L, Comi G, Montalban X, et al. Oral FTY720 (fingolimod) in relapsing multiple sclerosis: impact on patient-reported depression, as measured by the Beck Depression Inventory II in a 6-month, placebo-controlled study. Neurology. 2007;68:A276.5

Exclusion codes: 2=ineligible outcome, 5=ineligible publication type

Copyright © 2011 by Oregon Health & Science University.
Bookshelf ID: NBK65426
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.3M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...